PMC:7195088 / 23456-23976 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T115","span":{"begin":106,"end":114},"obj":"Disease"},{"id":"T116","span":{"begin":393,"end":401},"obj":"Disease"},{"id":"T117","span":{"begin":471,"end":479},"obj":"Disease"}],"attributes":[{"id":"A115","pred":"mondo_id","subj":"T115","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A116","pred":"mondo_id","subj":"T116","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A117","pred":"mondo_id","subj":"T117","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Comparison of oseltamivir plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with mild COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19. Open-label RCT (NCT04303299, not yet recruiting). Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T117","span":{"begin":408,"end":413},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"}],"text":"Comparison of oseltamivir plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with mild COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19. Open-label RCT (NCT04303299, not yet recruiting). Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T280","span":{"begin":14,"end":25},"obj":"Chemical"},{"id":"T281","span":{"begin":31,"end":42},"obj":"Chemical"},{"id":"T282","span":{"begin":47,"end":58},"obj":"Chemical"},{"id":"T283","span":{"begin":64,"end":83},"obj":"Chemical"},{"id":"T284","span":{"begin":64,"end":73},"obj":"Chemical"},{"id":"T285","span":{"begin":74,"end":83},"obj":"Chemical"},{"id":"T286","span":{"begin":122,"end":141},"obj":"Chemical"},{"id":"T287","span":{"begin":122,"end":131},"obj":"Chemical"},{"id":"T288","span":{"begin":132,"end":141},"obj":"Chemical"},{"id":"T289","span":{"begin":147,"end":158},"obj":"Chemical"},{"id":"T290","span":{"begin":163,"end":172},"obj":"Chemical"},{"id":"T291","span":{"begin":173,"end":182},"obj":"Chemical"},{"id":"T292","span":{"begin":188,"end":199},"obj":"Chemical"},{"id":"T293","span":{"begin":204,"end":215},"obj":"Chemical"},{"id":"T294","span":{"begin":221,"end":240},"obj":"Chemical"},{"id":"T295","span":{"begin":221,"end":230},"obj":"Chemical"},{"id":"T296","span":{"begin":231,"end":240},"obj":"Chemical"},{"id":"T297","span":{"begin":245,"end":254},"obj":"Chemical"},{"id":"T298","span":{"begin":255,"end":264},"obj":"Chemical"},{"id":"T299","span":{"begin":270,"end":281},"obj":"Chemical"},{"id":"T300","span":{"begin":287,"end":298},"obj":"Chemical"},{"id":"T301","span":{"begin":303,"end":312},"obj":"Chemical"},{"id":"T302","span":{"begin":313,"end":322},"obj":"Chemical"},{"id":"T303","span":{"begin":328,"end":339},"obj":"Chemical"},{"id":"T304","span":{"begin":345,"end":356},"obj":"Chemical"},{"id":"T305","span":{"begin":408,"end":413},"obj":"Chemical"}],"attributes":[{"id":"A280","pred":"chebi_id","subj":"T280","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A281","pred":"chebi_id","subj":"T281","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A282","pred":"chebi_id","subj":"T282","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A283","pred":"chebi_id","subj":"T283","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A284","pred":"chebi_id","subj":"T284","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A285","pred":"chebi_id","subj":"T285","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A286","pred":"chebi_id","subj":"T286","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A287","pred":"chebi_id","subj":"T287","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A288","pred":"chebi_id","subj":"T288","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A289","pred":"chebi_id","subj":"T289","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A290","pred":"chebi_id","subj":"T290","obj":"http://purl.obolibrary.org/obo/CHEBI_367163"},{"id":"A291","pred":"chebi_id","subj":"T291","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A292","pred":"chebi_id","subj":"T292","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A293","pred":"chebi_id","subj":"T293","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A294","pred":"chebi_id","subj":"T294","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A295","pred":"chebi_id","subj":"T295","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A296","pred":"chebi_id","subj":"T296","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A297","pred":"chebi_id","subj":"T297","obj":"http://purl.obolibrary.org/obo/CHEBI_367163"},{"id":"A298","pred":"chebi_id","subj":"T298","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A299","pred":"chebi_id","subj":"T299","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A300","pred":"chebi_id","subj":"T300","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A301","pred":"chebi_id","subj":"T301","obj":"http://purl.obolibrary.org/obo/CHEBI_367163"},{"id":"A302","pred":"chebi_id","subj":"T302","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A303","pred":"chebi_id","subj":"T303","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A304","pred":"chebi_id","subj":"T304","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A305","pred":"chebi_id","subj":"T305","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"}],"text":"Comparison of oseltamivir plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with mild COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19. Open-label RCT (NCT04303299, not yet recruiting). Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T175","span":{"begin":403,"end":452},"obj":"Sentence"},{"id":"T176","span":{"begin":453,"end":520},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Comparison of oseltamivir plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with mild COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19. Open-label RCT (NCT04303299, not yet recruiting). Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks)."}